OPTINOSE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.82 USD | -9.39% |
|
-6.62% | -35.27% |
Financials (USD)
| Sales 2024 * | 91.38M | Sales 2025 * | 130M | Capitalization | 102M |
|---|---|---|---|---|---|
| Net income 2024 * | -30M | Net income 2025 * | -11M | EV / Sales 2024 * | 1.12 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.78 x |
| P/E ratio 2024 * |
-3.48
x | P/E ratio 2025 * |
-10.1
x | Employees | 132 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on OptiNose, Inc.
More recommendations
More press releases
| 1 day | -2.21% | ||
| 1 week | -2.45% | ||
| Current month | -38.01% | ||
| 1 month | -39.67% | ||
| 3 months | -38.01% | ||
| 6 months | -23.63% | ||
| Current year | -29.84% |
1 week
0.86
1.25
1 month
0.861.50
Current year
0.862.10
1 year
0.862.10
3 years
0.864.30
5 years
0.8611.66
10 years
0.8630.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ramy Mahmoud
CEO | Chief Executive Officer | 59 | 09-12-31 |
| Chief Tech/Sci/R&D Officer | - | 17-05-31 | |
John C. Messina
CTO | Chief Tech/Sci/R&D Officer | - | 09-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 17-09-30 | |
Sandra Helton
BRD | Director/Board Member | 74 | 18-02-21 |
Eric Bednarski
BRD | Director/Board Member | 53 | 21-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.8312 | -8.15% | 2 290 023 |
| 24-04-25 | 0.905 | -2.19% | 23,397,083 |
| 24-04-24 | 0.9253 | -4.38% | 571,325 |
| 24-04-23 | 0.9677 | -6.05% | 671,645 |
| 24-04-22 | 1.03 | +15.19% | 1,263,463 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.905
USD
Average target price
3.75
USD
Spread / Average Target
+314.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.84% | 102M | |
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- OPTN Stock
